Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can this A$653m raise turn PYC Therapeutics (ASX: PYC) into a global RNA frontrunner?
PYC Therapeutics is raising A$653M to fund four RNA therapies into human efficacy trials. Find out what this means for investors and the biotech sector.
Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.
Can Coya Therapeutics de-risk IL-2 manufacturing ahead of trial results? Inside the $11.1m raise
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy’s to scale COYA 302 IL-2 manufacturing. Find out what it means for investors.
Johnson & Johnson’s AKEEGA clears major EU hurdle with CHMP nod for mHSPC BRCA mutation indication
Johnson & Johnson’s EU backing for AKEEGA’s expanded prostate cancer label could reshape its oncology strategy and precision medicine footprint in 2026.
Can weight loss drugs cause fatal pancreas illness? UK raises red flag on GLP-1 therapies
UK strengthens pancreatitis risk warning for GLP-1 weight loss and diabetes drugs like Wegovy and Mounjaro. Find out what it means for health systems and pharma.
Moderna shakes up leadership as COVID vaccine demand wanes—can new R&D head realign its future?
Find out why Moderna, Inc. is replacing its medical chief with a development leader and what it means for the company’s post-COVID pipeline strategy.
EMA moves Protalix (PLX) closer to extended dosing approval for Elfabrio in Fabry disease
Protalix BioTherapeutics secures EMA panel backing for monthly Elfabrio dosing in Fabry disease, unlocking a $25M milestone. See what it means for PLX.
Castanospermine commercialization strategy evolves as Sixty Degrees Pharmaceuticals pursues non prescription market entry
Discover why Sixty Degrees Pharmaceuticals is shifting castanospermine toward non prescription market entry and what this means for execution, risk, and investor strategy.
Incyte breaks new ground in EU cancer care with first PD‑1 drug for tough gastrointestinal tumors
Discover how Incyte’s EU backing for its MacroGenics‑partnered cancer drug Zynyz could shift immunotherapy competition in gastrointestinal cancers.
Why did Amgen Inc. walk away from its $1.25bn eczema drug deal with Kyowa Kirin?
Amgen Inc. exits its $1.25B eczema drug deal with Kyowa Kirin Co., Ltd., reshaping its immunology focus. Find out what this move means for both companies’ pipelines.